This is a well-known side effect of mTOR inhibitors such as everolimus, with pneumonitis seen in both the BOLERO-2 trial (3%) and PrE0102 trial (17% overall, 6% grade 3) [24, 25]. Here, MTOR is linked to pneumonitis.